Low-Dose Chemotherapy · Evidence & Safety

Insulin Potentiation Therapy for Cancer: What Patients Should Know

Insulin potentiation therapy (IPT) combines insulin-induced low blood sugar with lower-than-standard doses of chemotherapy. The theory is that insulin may make cancer cells more sensitive to treatment, but this has not been established in well-designed trials and IPT has not been shown to provide the same cancer control as standard-dose chemotherapy.

At Sunridge Medical, questions about IPT deserve an honest, individualized review: what has already been tried, whether a proven dose-adjusted regimen exists, how treatment goals affect the decision, and how hypoglycemia and under-treatment risks would be addressed.

Evidence explained clearlyHypoglycemia safety emphasizedOncology coordination encouraged

Request an Integrative Review →Call 1-800-923-7878

Scientific cancer research scene illustrating insulin, glucose metabolism and tumor cells — IPT is based on a metabolic hypothesis, but laboratory plausibility and limited early studies do not establish equivalent cancer outcomes.

IPT consultation

Understand the Tradeoffs Before Considering IPT

Insulin potentiation therapy involves significant questions about chemotherapy dosing, glucose safety and evidence. Our Patient Care Team can help collect the oncology records and questions needed for a direct, physician-led discussion.

Chemotherapy dose and evidence questions are addressed directly
Glucose safety and medical supervision are essential
Call now for an immediate response from our Patient Care Team

Call 1-800-923-7878 →

IPT consultation

Speak With Our Patient Care Team

Tell us what you have been advised about IPT and where you are in cancer treatment. We will help you plan a careful conversation.

* Required fields

Prefer to speak with someone now?

1-800-923-7878

Chemotherapy dose and evidence questions are addressed directly
Glucose safety and medical supervision are essential
Questions before scheduling are always welcome

IPT · Key Points

The Most Important Answers First

Evidence

IPT remains unproven

Only very small clinical studies have been published. They do not demonstrate that IPT improves survival or matches standard chemotherapy.

Dose

Lower dose is not automatically equivalent

Many chemotherapy regimens depend on validated drug, dose and schedule combinations. Reducing them without evidence can risk inadequate treatment.

Safety

Insulin can cause dangerous hypoglycemia

Confusion, sweating, tremor, seizure, loss of consciousness and other complications can occur when blood glucose falls too low.

Next Step

Start with the treatment goal

Curative, disease-control and symptom-relief settings require different risk-benefit discussions and different evidence thresholds.

Background

What Is Insulin Potentiation Therapy?

IPT generally involves fasting, intravenous insulin, a fall in blood glucose, administration of reduced-dose chemotherapy and then glucose to reverse the hypoglycemia. Protocols vary, and there is no universally accepted IPT regimen.

The proposed rationale is that insulin signaling, glucose transport and cell-cycle effects might increase tumor-cell sensitivity to certain drugs. In-vitro studies have reported enhanced chemotherapy effects in some cell models. That research is hypothesis-generating—not proof that insulin selectively delivers chemotherapy to a human tumor or protects normal tissue.

“Cancer feeds on sugar” is an oversimplification

Tumors use multiple fuels and metabolic pathways. Insulin affects normal cells as well as cancer cells, and a PET scan’s glucose uptake does not prove that insulin can safely target chemotherapy only to a tumor.

Clinical Research

What the Human Studies Actually Show

Small metastatic breast cancer trial

A 2004 trial randomized 30 patients to insulin plus methotrexate, methotrexate alone or insulin alone. Short-term disease stability favored the combination, but there were only ten patients per group, brief treatment and no evidence that IPT was equivalent to an accepted chemotherapy regimen or improved survival.

Small prostate cancer series

A 2012 report described 16 patients with castration-resistant prostate cancer who received insulin with low-dose chemotherapy and hormone therapy. It had no standard-treatment control group and was too small to establish efficacy.

A lung cancer publication described one patient, and laboratory studies have reported sensitization in cell lines. These findings may justify further research, but they cannot support broad claims that IPT targets cancer, avoids normal-cell injury or works as well as standard-dose chemotherapy.

Best interpretation: IPT has a biologic hypothesis and preliminary signals, but reliable patient benefit has not been established.

Safety & Monitoring

Two Different Risks Must Be Considered

Oncology physician reviewing glucose monitoring and treatment timing with a cancer patient — A responsible review covers both immediate insulin safety and the longer-term risk of receiving an inadequately tested chemotherapy dose.

Immediate insulin risk

Symptomatic or severe hypoglycemia
Confusion, weakness, seizure or loss of consciousness
Medication interactions and glucose-management complexity
Need for close monitoring and rapid rescue capability

Oncology risk

Receiving less chemotherapy than a validated regimen requires
Delaying treatment with established benefit
Using response claims that are not supported by controlled trials
Losing time during progressive or potentially curable disease

Chemotherapy Context

Why Dose and Schedule Cannot Be Separated From Evidence

Oncologists sometimes reduce doses, change schedules or select gentler regimens for age, organ function, prior toxicity, goals of care or patient preference. Those decisions can be appropriate when they are based on data and the individual case. That is different from assuming insulin makes one-tenth of a standard dose equally effective.

Research across several cancers has associated lower relative dose intensity with poorer outcomes, although the importance varies by cancer, regimen and intent. The right comparison is not “IPT versus nothing”; it is IPT versus the best evidence-based and tolerable options still available.

Shared Decision-Making

Questions to Ask Before Considering IPT

Goal

Is treatment intended to cure, control or relieve?

The acceptable uncertainty is very different when proven curative treatment may still be available.

Comparator

What validated options remain?

Ask about standard therapy, evidence-based reduced-dose regimens, supportive care and clinical trials.

Measurement

How will benefit be assessed?

Define imaging, laboratory, symptom and stopping criteria before treatment starts.

Safety

How is severe hypoglycemia managed?

Confirm monitoring, rescue procedures, qualified supervision and emergency readiness.

Sunridge Medical Approach

A Positive Plan Can Still Be Evidence-Aware

Patients often ask about IPT because standard chemotherapy has been difficult, because disease has progressed, or because quality of life matters deeply. Those concerns are legitimate. A thoughtful integrative consultation can explore them without promising that an investigational lower dose will provide the same tumor control.

Review pathology, stage, biomarkers, prior treatments and current scans
Clarify the goal of care and the patient’s priorities
Discuss proven dose-modified regimens and clinical trials when relevant
Address nutrition, fatigue, pain, sleep and treatment tolerance
Coordinate decisions with the treating oncology team whenever possible

Frequently Asked Questions

IPT and Cancer Questions

Is IPT proven to treat cancer?

No. The published human evidence is too small and limited to establish improved survival, durable tumor control or equivalence to standard chemotherapy.

Is IPT approved by the FDA as a cancer treatment?

No specific IPT regimen is FDA-approved to treat cancer. Insulin and chemotherapy drugs may be approved individually, but combining them in this way is an off-label, investigational approach.

Does insulin selectively open cancer cells?

That is a promotional simplification, not a proven clinical mechanism. Insulin signaling affects normal and malignant cells, and selective tumor delivery has not been established.

Does IPT use one-tenth of a chemotherapy dose?

Some protocols use very low doses, but protocols vary. There is no reliable evidence that one-tenth of a validated chemotherapy dose provides equivalent cancer control.

Does IPT avoid chemotherapy side effects?

Lower drug exposure may reduce some toxicities, but chemotherapy can still cause harm and insulin introduces hypoglycemia risk. Lower toxicity does not establish adequate anticancer effect.

What is the main immediate risk?

Hypoglycemia can cause sweating, tremor, confusion, seizure or loss of consciousness and requires close monitoring and rapid treatment.

What if standard chemotherapy was too difficult?

Ask about evidence-based dose modification, an alternate regimen, supportive medications, schedule changes, rehabilitation, nutrition and clinical trials before assuming IPT is the best option.

Can IPT be used after cancer progression?

Progression makes a fresh pathology, biomarker, trial and treatment review especially important. Limited options do not make an investigational therapy proven.

Can integrative care still help if I do not choose IPT?

Yes. Integrative care may address pain, fatigue, sleep, nutrition, anxiety, mobility and treatment tolerance alongside disease-directed oncology.

Can Sunridge review my case and goals?

Yes. A consultation can evaluate the records, clarify the evidence and help identify safer, more defensible options for your situation.

Primary Sources & Evidence Reviews

References

This page is educational and does not replace individual medical advice. IPT remains unproven for cancer and should not delay treatment with established benefit or clinical-trial evaluation.

Considering a Different Treatment Path?

Start With Your Diagnosis, Goals and the Strongest Available Evidence

Our Patient Care Team can help determine which records are needed for a physician-directed review of prior treatment, quality-of-life concerns, IPT questions and other integrative options.

Request a Cancer Consultation →Call 1-800-923-7878

Living research library · positive published findings

Research organized by cancer type

Browse 5 source-linked studies with the full title, publication year, research focus and a concise finding. Select any linked cancer type to move directly to its corresponding Sunridge page.

Search the library

Cancer type

Breast cancer

Insulin-induced enhancement of antitumoral response to methotrexate in breast cancer patients

2004 · Survival and clinical response

In a randomized study of multidrug-resistant metastatic breast cancer, insulin plus methotrexate produced greater disease control than either treatment used separately.

Open study on PubMed →

Breast cancer

Insulin-induced enhancement of MCF-7 breast cancer cell response to 5-fluorouracil and cyclophosphamide

2017 · Treatment response

Insulin sensitized breast-cancer cells to 5-fluorouracil and cyclophosphamide through cell-cycle and drug-transport-associated mechanisms.

Open study on PubMed →

Colorectal cancer

Insulin enhancement of the antitumor activity of chemotherapeutic agents in colorectal cancer is linked with downregulating PIK3CA and GRB2

2020 · Treatment response

Insulin pretreatment increased colorectal-cancer-cell susceptibility to several chemotherapies; insulin plus 5-FU also inhibited tumor growth and reduced circulating tumor cells in the reported model.

Open study on PubMed →

Colorectal cancer

Insulin induces anticancer cytotoxicity of 5-FU to two human colon cancer cell lines

2010 · Treatment response

Insulin increased the growth-inhibitory response of two colorectal-cancer cell lines to 5-fluorouracil and increased the proportion of cells in S phase.

Open study on PubMed →

Prostate cancer

Low-dose chemotherapy with insulin (insulin potentiation therapy) in combination with hormone therapy for treatment of castration-resistant prostate cancer

2012 · Survival and clinical response

A small clinical series reported partial PSA responses in half of the participants and stabilization in another quarter after insulin-potentiated low-dose chemotherapy.

Open study on PubMed →

Find the right place to begin

Conditions & Care

Treatments & Therapies

Plan Your Care

Cancer care that happens here

Start Here

Cancers We Treat

Treatment & Planning

Find the right place to begin

Conditions & Care

Treatments & Therapies

Plan Your Care

Cancer care that happens here

Start Here

Cancers We Treat

Treatment & Planning

Insulin Potentiation Therapy for Cancer: What Patients Should Know

Understand the Tradeoffs Before Considering IPT

Speak With Our Patient Care Team

The Most Important Answers First

IPT remains unproven

Lower dose is not automatically equivalent

Insulin can cause dangerous hypoglycemia

Start with the treatment goal

What Is Insulin Potentiation Therapy?

“Cancer feeds on sugar” is an oversimplification

What the Human Studies Actually Show

Small metastatic breast cancer trial

Small prostate cancer series

Two Different Risks Must Be Considered

Immediate insulin risk

Oncology risk

Why Dose and Schedule Cannot Be Separated From Evidence

Questions to Ask Before Considering IPT

Is treatment intended to cure, control or relieve?

What validated options remain?

How will benefit be assessed?

How is severe hypoglycemia managed?

A Positive Plan Can Still Be Evidence-Aware

IPT and Cancer Questions

References

Start With Your Diagnosis, Goals and the Strongest Available Evidence

Research organized by cancer type

Insulin-induced enhancement of antitumoral response to methotrexate in breast cancer patients

Insulin-induced enhancement of MCF-7 breast cancer cell response to 5-fluorouracil and cyclophosphamide

Insulin enhancement of the antitumor activity of chemotherapeutic agents in colorectal cancer is linked with downregulating PIK3CA and GRB2

Insulin induces anticancer cytotoxicity of 5-FU to two human colon cancer cell lines

Low-dose chemotherapy with insulin (insulin potentiation therapy) in combination with hormone therapy for treatment of castration-resistant prostate cancer

Explore Care

Services & Shop

Stay Connected

Scottsdale Clinic

Call Our Care Team

Email

Office Hours

Visit Sunridge in Scottsdale

Speak With Our Patient Care Team

Have a Question or Share Feedback:

It's easy to get in touch with us